“Finding non-toxigenic Clostridium difficile (C.diff) in the gut flora of all 119 subjects tested by genetic sequencing raises the question whether C.diff is an innocent bystander or villain and if antibiotics should be used to kill something that is part of our microbial fingerprint,” says Progenabiome CEO Sabine Hazan, MD, “this breakthrough in research challenges us to look beyond the traditional protocols to treat bacteria and viruses automatically with drugs. It also forces us to understand the balance of the microbiome that allows for immunity to occur.”
Hazan has been a solo practice gastroenterologist and clinical trials investigator for 25+ years. She has participated in over 150 clinical trials for the pharmaceutical and nutrition industries and launched Progenabiome in 2018 to investigate the role of the gut microbiome in various diseases and conditions.
Strategically placed as a genetic sequencing lab, site, CRO, and now sponsor, Progenabiome has 39 ongoing clini